Know Cancer

or
forgot password

Trimodality Therapy for Malignant Pleural Mesothelioma: Radical Pleurectomy, Followed by Adjuvant Chemotherapy With Cisplatin/Pemetrexed and Radiotherapy


N/A
18 Years
N/A
Open (Enrolling)
Both
Malignant Pleural Mesothelioma

Thank you

Trial Information

Trimodality Therapy for Malignant Pleural Mesothelioma: Radical Pleurectomy, Followed by Adjuvant Chemotherapy With Cisplatin/Pemetrexed and Radiotherapy


Inclusion Criteria:



- Histologically confirmed diagnosis of MPM (all subtypes)

- Clinical T1-3, N0-2, M0 disease.

- No prior treatment for MPM.

- Adequate renal and liver function

- Adequate cardio-pulmonary reserves

Exclusion Criteria:

- Patients with unresectable disease

- Patients with an active infection that require systemic treatments

- Patients with a concurrent active malignancy.

- Patients with serious medical illness.

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Outcome Measure:

To determine the overall 5-year survival rate.

Outcome Time Frame:

5-years

Safety Issue:

Yes

Principal Investigator

Joachim Schirren, MD, PhD

Investigator Role:

Principal Investigator

Investigator Affiliation:

HSK Wiesbaden

Authority:

Germany: Ethics Commission

Study ID:

RP2002-01

NCT ID:

NCT01343264

Start Date:

November 2002

Completion Date:

Related Keywords:

  • Malignant Pleural Mesothelioma
  • Radical Pleurectomy
  • Pleurectomy/decortication
  • Cisplatin
  • Pemetrexed
  • Radiation
  • Mesothelioma

Name

Location